XFOR Earnings

Quarterly EPS
$-5.48
Q3 2024
$-5.89
Q4 2024
$0.04
Q1 2025
$-3.47
Q2 2025
$-0.69
Q3 2025
$-0.21
Q4 2025
$-0.16
Q1 2026
$-0.13
Q2 2026
Latest Revenue8.8M
Latest Net Income-16157000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.138.8M-16157000+346.3%+96.3%
Q1 2026-$0.162.7M-20241000-90.6%-500.0%
Q4 2025-$0.212.6M-23925000+79.1%+96.4%
Q3 2025-$0.691.8M-29815000+215.2%+87.4%
Q2 2025-$3.472.0M-25741000+250.4%-125.5%
Q1 2025$0.0428.8M282.0K+100.5%
Q4 2024-$5.891.4M-39821000-104.5%
Q3 2024-$5.48560.0K-36696000-1,726.7%
Q2 2024$13.59563.0K90.8M
Q1 2024-$7.77-51766000
Q4 2023-$2.88-19130000
Q3 2023-$0.30-2305000
X4 Pharmaceuticals (XFOR) — Earnings